| 1.19 -0.02 (-1.65%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.61 |
1-year : | 1.88 |
| Resists | First : | 1.37 |
Second : | 1.61 |
| Pivot price | 1.07 |
|||
| Supports | First : | 1.14 |
Second : | 0.99 |
| MAs | MA(5) : | 1.1 |
MA(20) : | 1.08 |
| MA(100) : | 1.22 |
MA(250) : | 1.27 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 58.8 |
D(3) : | 45.7 |
| RSI | RSI(14): 61.3 |
|||
| 52-week | High : | 2.24 | Low : | 0.77 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CRDL ] has closed Bollinger Bands are 33.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.38 - 1.39 | 1.39 - 1.4 |
| Low: | 1.11 - 1.12 | 1.12 - 1.13 |
| Close: | 1.18 - 1.19 | 1.19 - 1.2 |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Wed, 22 Oct 2025
(CRDL) Stock Analysis and Trading Signals (CRDL:CA) - news.stocktradersdaily.com
Tue, 21 Oct 2025
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027 - Newsfile
Tue, 21 Oct 2025
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027 - Stock Titan
Mon, 20 Oct 2025
Canadian Investment Regulatory Organization Trade Resumption - CRDL - Investing News Network
Fri, 17 Oct 2025
Cardiol Therapeutics Inc. (CRDL) Stock Drops After $11 Million Private Placement Announcement - parameter.io
Fri, 17 Oct 2025
Cardiol Therapeutics raises $11 million to advance heart disease therapies By Investing.com - Investing.com Nigeria
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 84 (M) |
| Shares Float | 81 (M) |
| Held by Insiders | 4.1 (%) |
| Held by Institutions | 8.4 (%) |
| Shares Short | 2,200 (K) |
| Shares Short P.Month | 2,400 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -108.8 % |
| Return on Equity (ttm) | -276.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -3.51 |
| PEG Ratio | 0 |
| Price to Book value | 8.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|